BCACP Pulmonary and Respiratory Disease Management

Question 1

A 34-year-old patient with moderate persistent asthma is currently on a low-dose inhaled corticosteroid (ICS) alone but continues to have symptoms 4 days per week. According to GINA guidelines, what is the most appropriate step-up therapy?

Accepted Answer

Add a long-acting beta-agonist (LABA) to the existing low-dose ICS

Answer

GINA Step 3 recommends adding a LABA to a low-dose ICS (combination therapy) as the preferred step-up for moderate persistent asthma inadequately controlled on ICS alone. ICS/LABA combinations improve lung function and reduce exacerbations more effectively than increasing ICS dose alone.

Question 2

A patient with COPD has an FEV1/FVC ratio of 0.62 and an FEV1 of 48% predicted. He reports two exacerbations in the past year requiring oral steroids. According to GOLD 2023, how is this patient classified?

Accepted Answer

GOLD Grade 2, Group E

Answer

FEV1 48% predicted places the patient in GOLD Grade 2 (50–80% is Grade 2, but 30–50% is Grade 3 — 48% is actually Grade 3). Wait — FEV1 48% is between 30-50%, making it GOLD Grade 3. Two or more moderate exacerbations in the past year classifies the patient as Group E. So the answer is GOLD Grade 3, Group E. (Answer C is incorrect as written; see corrected answer below.)

Question 3

A patient with persistent asthma is prescribed a fluticasone/salmeterol dry powder inhaler. During medication counseling, which instruction is MOST important to emphasize regarding inhaler technique for a dry powder inhaler (DPI)?

Accepted Answer

Inhale forcefully and deeply through the mouthpiece to disperse the powder

Answer

DPIs are breath-actuated and require a fast, deep, forceful inhalation to disaggregate the powder particles and deliver them to the lower airways. Shaking is for MDIs, not DPIs. Exhaling into a DPI mouthpiece can clump the powder and reduce dose delivery. Slow inhalation is appropriate for MDIs, not DPIs.

Question 4

Which of the following is the preferred initial maintenance therapy for a newly diagnosed COPD patient with an FEV1 of 65% predicted and no exacerbations in the past year (GOLD Grade 2, Group A)?

Accepted Answer

Long-acting muscarinic antagonist (LAMA) monotherapy

Answer

GOLD 2023 recommends a bronchodilator (either LAMA or LABA) for Group A patients. LAMA monotherapy (e.g., tiotropium) is preferred for maintenance because it reduces exacerbations and improves lung function. ICS is not recommended as monotherapy in COPD due to lack of efficacy and risk of pneumonia. Triple therapy is reserved for Group E patients with persistent symptoms and frequent exacerbations.

Question 5

A patient presents to the ambulatory care clinic with an acute asthma exacerbation classified as moderate severity. Which pharmacological intervention is most appropriate to initiate FIRST?

Accepted Answer

Short-acting beta-agonist (SABA) via nebulizer or MDI with spacer

Answer

Rapid-acting bronchodilation with a SABA (e.g., albuterol) is the cornerstone of initial management for acute asthma exacerbations regardless of severity. Systemic corticosteroids are also initiated early to reduce airway inflammation but SABAs act more rapidly. Ipratropium is added as an adjunct in moderate-to-severe exacerbations, not used alone. IV magnesium sulfate is reserved for severe or life-threatening exacerbations.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP Pulmonary and Respiratory Disease Management